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Abstract
Activity and selectivity assessment of new bi-aryl amide 11β-hydroxysteroid dehydrogenase 1
(11β-HSD1) inhibitors, prepared in a modular manner via Suzuki cross-coupling, are described.
Several compounds inhibiting 11β-HSD1 at nanomolar concentrations were identified. Com-
pounds 2b, 3e, 7b and 12e were shown to selectively inhibit 11β-HSD1 over 11β-HSD2, 17β-
HSD1 and 17β-HSD2. These inhibitors also potently inhibited 11β-HSD1 activity in intact HEK-
293 cells expressing the recombinant enzyme and in intact primary human keratinocytes
expressing endogenous 11β-HSD1. Moreover, compounds 2b, 3e and 12e were tested for
their activity in human skin biopsies. They were able to prevent, at least in part, both the corti-
sone- and the UV-mediated decreases in collagen content. Thus, inhibition of 11β-HSD1 by
these compounds can be further investigated to delay or prevent UV-mediated skin damage
and skin aging.
Introduction
With an aging population, UV-mediated skin damage and skin aging-related diseases repre-
sent an increasing problem and there is an increasing demand for novel therapies against skin
diseases [1]. Excessive exposure to UV light results in skin damage, with erythema and DNA
damage, oxidative stress, and an inflammatory response with the production of pro-inflamma-
tory mediators such as tumor necrosis factor α (TNFα), interleukin 6 (IL6) and interleukin 1β
(IL1β), and the activation of nuclear factor-κB (NF-κB) [2–4]. Glucocorticoids play an impor-
tant immune modulatory role and by activating glucocorticoid receptors (GR) they suppress
the expression of pro-inflammatory cytokines and activation of NF-κB, thereby aiding in the
resolution of the inflammatory response [5].
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Human skin has the capacity to produce glucocorticoids, androgens and estrogens from de
novo synthesis of cholesterol via the steroidogenic pathway [6–10]. Besides, the local concen-
tration of cortisol is controlled by 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes,
catalyzing the interconversion of active cortisol and inactive cortisone [11]. 11β-HSD1 is a
bidirectional enzyme utilizing cofactor NADPH and acts in vivo predominantly as an oxo-
reductase converting cortisone to cortisol [12]. It is widely expressed; in skin it has been
detected in keratinocytes, dermal fibroblasts and the outer root sheath of hair follicles [13]. In
contrast, 11β-HSD2 utilizes cofactor NAD+, oxidizes cortisol to cortisone, and is expressed in
mineralocorticoid target tissues such as kidney, colon and salivary gland but also in placenta
[11], and it has also been found in keratinocytes [14, 15].
The production of glucocorticoids in skin has been shown to be strongly influenced by
ultraviolet (UV) radiation. On one hand it has been shown that UVB results in an activation of
a dermal regulatory system analogous to that of the hypothalamus-pituitary-adrenal (HPA)
axis and stimulation of steroidogenic de novo synthesis of cortisol [8, 16, 17], and on the other
hand UVB and UVC (but not UVA) exposure led to an enhanced expression of 11β-HSD1 but
had no effect on 11β-HSD2 (which was increased by UVA) [14]. These observations indicate
that UVB exposure results in increased dermal cortisol production.
Due to their potent effects on the regulation of immune responses, synthetic glucocorticoids
are widely used to treat acute and chronic inflammatory diseases [18, 19]. In this respect, topical
application of glucocorticoids represent the main treatment option for inflammatory dermatitis,
aiming to reduce the infiltration of the skin by inflammatory cells and suppressing inflamma-
tory effects on keratinocytes [20]. Nevertheless, both prolonged systemic and topical treatment
with glucocorticoids are known to cause skin atrophy, due to effects on collagen synthesis and
degradation and by impacting on keratinocyte and fibroblast proliferation [21–28].
Similarly, chronically elevated 11β-HSD1 activity in aging skin may contribute to glucocor-
ticoid-induced dermal and epidermal thinning and dermal-epidermal junction flattening,
reduced dermal fibroblast proliferation and impairment of collagen content [29–32]. Studies
in mice deficient in 11β-HSD1 showed higher collagen density, better structured collagen
organization and delayed age-induced dermal atrophy compared with age-matched wild-type
mice [32]. Additionally, treatment with a selective 11β-HSD1 inhibitor enhanced dermal
thickness and collagen content in mice, an effect suggested being a result of a higher number
of dermal fibroblasts [31]. Inhibition of 11β-HSD1 by topical and subcutaneous applications
of a selective compound increased the number of keratinocytes and dermal fibroblasts in mice
[31, 33]. Based on the above mentioned studies it was suggested that pharmacological inhibi-
tion of 11β-HSD1 may reverse the decreased collagen content observed in intrinsically and
extrinsically aged skin and in glucocorticoid-induced skin atrophy.
Several efforts have been devoted by both academic groups and the pharmaceutical industry
towards the discovery of selective 11β-HSD1 inhibitors [34]. The first selective 11β-HSD1
inhibitors, reported by Barf et al. [35], were 2-aminothiazoles. These have been followed by dif-
ferent structural classes, and several clinical candidates for the treatment of diabetes and meta-
bolic syndrome have been reported [34, 36]. In the present study, a series of novel biaryl amide
compounds was profiled for inhibitory activity against 11β-HSD1, selectivity over 11β-HSD2,
17β-HSD1, and 17β-HSD2, as well as activity in intact cells and ex vivo in human skin samples.
Materials and methods
Materials and methods for chemistry
Dichloromethane for amidation reactions was dried over sodium sulfate and diethyl ether was
dried over phosphoric anhydride, followed by storage under argon. All other reagents were
11β-HSD1 inhibitors for skin applications
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reagent or analytical grade and used as received (for a detailed description of the methods and
compounds see S1 File). All air- and water- sensitive reactions were performed under argon.
Water for cross-coupling reactions was degassed by sparging with argon under vacuum for 30
min prior to use. The catalytic 10 mM Pd(EDTA) solution was prepared from palladium(II)
chloride, ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate and sodium car-
bonate as described [37].
General synthesis strategies
Where not otherwise stated, the library compounds (see Fig 1, S1 Fig, S1 File) were prepared
by means of one of the following two-step synthesis strategies (Fig 2).
General strategy A. Step A1. In a round-bottomed flask 3-bromobenzoic acid was dis-
solved in anhydrous dichloromethane (5 mL/mmol) under stirring at room temperature and
1-hydroxybenzotriazole (HOBt, 1.11 eq) and N-(3-dimethylamino)-propyl-N’-ethyl-carbodii-
mide hydrochloride (EDC×HCl, 1.10 eq) were added. After quantitative activation (as judged
by UHPLC analysis), the required secondary amine a-f (1.2 eq) and N-ethyl-diisopropylamine
(DIEA, 1.5 eq) were added. After 30 min the mixture was concentrated under reduced pres-
sure, taken-up with ethyl acetate (AcOEt) (40 mL/mmol 3-bromobenzoic acid), washed with
5% KHSO4 (2×15 mL/mmol 3-bromobenzoic acid), H2O (12 mL/mmol 3-bromobenzoic
acid), 5% NaHCO3 (3×12 mL/mmol 3-bromobenzoic acid) and brine (12 mL/mmol 3-bromo-
benzoic acid), dried over Na2SO4, filtered and evaporated to dryness under reduced pressure
to yield aryl bromide intermediate 13a-f.
Step A2. The aryl bromide derivative 13a-f obtained in the previous step, aryl boronic acid
y1-12 (1.1 eq), K2CO3 (3 eq) and palladium(0) tetrakis(triphenylphosphine) (0.02 eq) were
given in this order in a screw-cap reactor, a 8:8:1 toluene/EtOH/H2O mixture (8.5 mL/mmol
13a-f) was added, the reactor was closed tightly and heated to 100˚C under stirring. After 4 h
the mixture was cooled to room temperature, diluted with H2O (12 mL/mmol 13a-f), extracted
with AcOEt (2×25 mL/mmol 13a-f), the pooled organic phases were washed with 5% NaHCO3
(2×12 mL/mmol 13a-f) and brine (12 mL/mmol 13a-f), dried over Na2SO4, filtered and evapo-
rated to dryness under reduced pressure. If necessary, the crude product (1–12)(a-f) was puri-
fied by preparative HPLC.
General strategy B. Step B1. To a suspension of 3-carboxyphenylboronic acid in 3:2
dichloromethane/acetonitrile (anhydrous, 5 mL/mmol) HOBt (1.11 eq) and EDC×HCl (1.10
eq) were added. After complete dissolution the required secondary amine a-f (1.2 eq) and
DIEA (1.5 eq) were added. After 30 min the mixture was concentrated under reduced pres-
sure, taken-up with AcOEt (40 mL/mmol boronic acid), washed with 2.5% KHSO4 (6×10 mL/
mmol boronic acid), H2O (2×12 mL/mmol boronic acid) and brine (12 mL/mmol boronic
acid), dried over Na2SO4, filtered and evaporated to dryness under reduced pressure. The
crude aryl boronic intermediate 14a-f was purified by preparative HPLC.
Fig 1. General structure of bi-aryl amide compounds.
doi:10.1371/journal.pone.0171079.g001
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Step B2. Aryl bromide x1-12, the aryl boronic acid derivative 14a-f obtained in the previ-
ous step (1.05 eq), Na2CO3 (2 eq) and N-tetrabutylammonium bromide (TBAB, 0.01 eq) were
given in this order in a screw-cap reactor. H2O (2.0 mL/mmol x1-12) and 10 mM Pd(EDTA)
solution (0.3 mL/mmol aryl x1-12) were added, the reactor was closed tightly and heated to
100˚C under stirring. After 5 h the mixture was cooled to room temperature, diluted with
AcOEt (40 mL/mmol x1-12), washed with 5% NaHCO3 (15 mL/mmol x1-12), H2O (15 mL/
mmol x1-12), 5% KHSO4 (15 mL/mmol x1-12) and brine (15 mL/mmol x1-12), dried over
Na2SO4, filtered and evaporated to dryness under reduced pressure. The crude product (1–12)
(a-f) was purified by preparative HPLC.
General strategy C. Step C1. To 3-bromobenzoic acid, aryl boronic acid y1-12 (1.1 eq),
K2CO3 (3 eq) and palladium(0) tetrakis(triphenylphosphine) were given in a screw-cap reac-
tor, a 8:8:1 toluene/EtOH/H2O mixture (8.5 mL/mmol 3-bromobenzoic acid) was added, the
reactor was closed tightly and heated to 100˚C under stirring. After 4 h the mixture was cooled
to room temperature, diluted with AcOEt (10 mL/mmol 3-bromobenzoic acid) and extracted
with 5% NaHCO3 (4×10 mL/mmol 3-bromobenzoic acid). The pooled basic extracts were
acidified to pH 3 by dropwise addition of concentrated HCl under stirring, and then extracted
with AcOEt (3×10 mL/mmol 3-bromobenzoic acid). The pooled organic extracts were washed
with water (10 mL/mmol 3-bromobenzoic acid) and brine (10 mL/mmol 3-bromobenzoic
Fig 2. The four strategies used for the synthesis of the library compounds (1–12)(a-f). Regents and reaction conditions: (i) N-
(3-dimethylamino)-propyl-N’-ethyl-carbodiimide hydrochloride (EDC×HCl), 1-hydroxybenzotriazole (HOBt), N-ethyl-diisopropylamine
(DIEA); (ii) arylboronic acid y1-12, base, palladium catalyst; (iii) aryl bromide x1-12, base, palladium catalyst; (iv) base, palladium catalyst;
(v) secondary amine a-f, EDC×HCl, HOBt, DIEA. Bases and catalysts used in the Suzuki-Miyaura cross-coupling steps are detailed in the
Materials and Methods section.
doi:10.1371/journal.pone.0171079.g002
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acid), dried over Na2SO4, filtered and evaporated to dryness under reduced pressure to yield
benzoic acid intermediate m1-12.
Step C2. In a round-bottomed flask HOBt (1.11 eq) and EDC×HCl (1.10 eq) were added to
a suspension of the benzoic acid derivative m1-12 obtained in step C1 in anhydrous dichloro-
methane (5 mL/mmol). After complete dissolution secondary amine a-f (1.2 eq) and DIEA
(1.5 eq) were added. After 30 min the mixture was concentrated under reduced pressure,
taken-up with AcOEt (40 mL/mmol m1-12), washed with 5% KHSO4 (2×15 mL/mmol m1-
12), H2O (12 mL/mmol m1-12), 5% NaHCO3 (3×12 mL/mmol m1-12) and brine (12 mL/
mmol benzoic acid), dried over Na2SO4, filtered and evaporated to dryness under reduced
pressure.
General strategy D. Step D1. Aryl bromide x1-12, 3-boronobenzoic acid (1.05 eq),
Na2CO3 (2 eq), TBAB (0.01 eq) were given in a screw-cap reactor. H2O (2 mL/mmol x1-12)
and 10 mM Pd(EDTA) solution (0.3 mL/mmol x1-12) were added, the reactor was closed tightly
and heated to 100˚C under stirring. After 5 hours the mixture was cooled to room temperature,
diluted with AcOEt (10 mL/mmol x1-12) and extracted with 5% NaHCO3 (4×10 mL/mmol x1-
12). The pooled basic extracts were acidified to pH 3 under stirring by dropwise addition of con-
centrated HCl and extracted with AcOEt (3×10 mL/mmol x1-12). The pooled organic extracts
were washed with H2O and brine (10 mL/mmol x1-12 each), dried over Na2SO4, filtered and
evaporated to dryness under reduced pressure to yield benzoic acid intermediate m1-12. If nec-
essary, the crude product was purified by preparative-HPLC.
Step D2. In a round-bottomed flask, HOBt (1.11 eq) and EDC×HCl (1.10 eq) were added
to a suspension of the benzoic acid derivative m1-12 obtained in step C1 in anhydrous dichlor-
omethane (5 mL/mmol). After complete dissolution secondary amine a-f (1.2 eq) and DIEA
(1.5 eq) were added. After 30 min the mixture was concentrated under reduced pressure,
taken-up with AcOEt (40 mL/mmol m1-12), washed with 5% KHSO4 (2×15 mL/mmol m1-
12), H2O (12 mL/mmol m1-12), 5% NaHCO3 (3×12 mL/mmol m1-12) and brine (12 mL/
mmol benzoic acid), dried over Na2SO4, filtered and evaporated to dryness under reduced
pressure.
Materials and permission for biological experiments
Test and reference compounds, if not otherwise stated, were synthesized as described above or
obtained of the highest grade available from Sigma-Aldrich (Buchs, Switzerland). Stock solu-
tions (10 mM, 1 mM) were prepared in dimethyl sulfoxide (DMSO). [1,2,6,7-3H]-cortisol,
[2,4,6,7-3H]-estrone and [2,4,6,7-3H]-estradiol were obtained from PerkinElmer (Boston, MA,
USA) and [1,2-3H]-cortisone from American Radiolabeled Chemicals (St.Louis, MO). Cell
culture media were purchased from Sigma Aldrich.
The biological experiments were performed under approval by the Bundesamt fu¨r Umwelt
(BAFU), Switzerland, permission numbers A130932 and A070126.
Preparation of cell lysates
Human embryonic kidney (HEK-293) cells either stably expressing human 11β-HSD1 and
H6PDH (HHH7 clone, [38]) or 11β-HSD2 (AT8 clone, [39]), or transiently expressing human
17β-HSD1 or 17β-HSD2, were cultivated in Dulbecco’s modified Eagle medium (DMEM)
containing 4.5 g/L glucose, 10% fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL strepto-
mycin, 1 × MEM nonessential amino acids, and 10 mM HEPES buffer, pH 7.4. Cells were
washed with phosphate-buffered saline (PBS), centrifuged for 4 min at 150 × g, and the cell
pellets were snap frozen on dry ice and stored at −80˚C until further use.
11β-HSD1 inhibitors for skin applications
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Determination of enzyme activity in cell lysates
Cell lysates were resuspended in TS2 buffer (100 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM
MgCl2, 250 mM sucrose, 20 mM Tris-HCl, pH 7.4), followed by sonication at 4˚C using a
Hielscher UP50H ultrasonic processor (0.3 cycle, 20 amplitude %, 20 impulses; Hielscher Ultra-
sonics GmbH, Teltow Germany). Cell lysates, reaction mixture, and either vehicle (DMSO) or
inhibitor were incubated for 10 min at 37˚C in a final volume of 22.2 μL. The solvent concentra-
tion was 0.1%. 17β-HSD1, 17β-HSD2, and 11β-HSD1 activities were measured in presence of
200 nM of the corresponding substrates, i.e. estrone, estradiol, or cortisone, as well as 450 μM of
either NADPH or NAD+. 11β-HSD2 activity was measured in the presence of 50 nM cortisol
and 500 μM NAD+. An amount of 50 nCi of radiolabeled tracer substrate was included in the
experiments. Reactions were stopped by adding an excess of unlabeled cortisone and cortisol
(1:1, 2 mM, in methanol) for 11β-HSD measurements and estrone and estradiol (1:1, 2 mM in
methanol) for 17β-HSD measurements. The steroids were separated by SIL G-25 TLC plates
(Macherey-Nagel, Oensingen, Switzerland), using methanol-chloroform (1:9) for cortisone/cor-
tisol and AcOEt-chloroform (1:4) for estrone/estradiol separation. The bands of the correspond-
ing steroids were excised, followed by scintillation counting and calculation of the amount of
substrate conversion. Data were obtained from at least three independent measurements. Gly-
cyrrhetinic acid (CTRL 1) was used as positive control for 11β-HSD1 and 11β-HSD2 inhibition,
apigenin (CTRL 2) for 17β-HSD1, and compound 22 from Vuorinen et al. [40](CTRL 3) for
17β-HSD2 inhibition.
11β-HSD1 activity assay in intact cells
HEK-293 cells co-expressing 11β-HSD1 and H6PDH were seeded in poly-L-lysine coated 96
well-plates (30’000 cells/well) and cultivated in DMEM. At 24 h post-seeding, the cells were
washed with charcoal-treated serum-free DMEM (cDMEM) and incubated for 3 h in 100 μL
cDMEM. Then, the medium was aspirated and replaced by 30 μL cDMEM. 10 μL of inhibitor
dissolved in cDMEM were added, followed by pre-incubation for 25 min at 37˚C and mea-
surement of enzyme activity by adding 200 nM cortisone containing 50 nCi of radiolabeled
tracer. The reactions were terminated after 30 min of incubation, followed by analysis of sub-
strate conversion as described above. Data were obtained from at least three independent
measurements.
Human epidermal keratinocytes obtained from CELLnTEC advanced Cell Systems (Berne,
Switzerland) were maintained in CnT-Prime medium (http://cellntec.com/products/cnt-pr/
#datasheet) at 37˚C. Cells were subcultivated before reaching confluence. After reaching 90%
of confluence, the keratinocytes were washed twice with PBS prior to change to cortisol-free
CnT-Prime medium (custom-made by CELLnTEC). Keratinocytes were incubated with 1000
nM cortisone in the absence or presence of inhibitors. Compound CAS 1009373-58-3 (CTRL
4, Merck Millipore, Darmstadt, Germany) was used as positive control. After 24 h cell culture
supernatants were collected and the amount of cortisol produced was measured on a Mulstis-
kan Ascent plate reader (MTX Lab Systems, Bradenton, FL) using the Cortisol Parameter
Assay Kit (R&D Systems, Minneapolis, MN) following the instructions by the manufacturer.
Cell viability was assessed using PrestoBlue1 Cell Viability Reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions.
Experiments with ex vivo skin biopsies
Ex vivo skin experiments were performed as contract research by Cutech Biotechnology fol-
lowing the Helsinki declaration and who obtained permission as well as informed consent
from the patient (Padova, Italy). Human skin from abdominal plastic surgery of a female
11β-HSD1 inhibitors for skin applications
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donor was used. Skin samples were cut in pieces of approximately 8 × 3 mm (diameter × thick-
ness) and cultured in an air-liquid interface in a perforated ring of stainless steel in contact
with culture medium (modified Williams’ E medium, Sigma Aldrich) up to day 6. The culture
medium was renewed on day 0 and day 3. The test compounds were applied topically and
renewed daily. The application was performed as follows: skin biopsies were gently cleaned
with a cotton pad and 4 μL of 10 μM or 100 μM test compound were applied on top of each
piece and covered with a 6 mm (diameter) delivery membrane (CoTran 9728 Controlled Cali-
per Ethylene Vinyl Acetate Membrane, 3M, St. Paul, MN, USA).
Skin biopsies were subjected to UV irradiation using a BIO-SUN system (Vilber Lourmat,
Eberhardzell, Germany). The system had the following specifications: Lamp wave length: UVB
312 nm (range 280–320 nm) and UVA 365 nm (range 355–375 nm), range of measure (irradi-
ance): accuracy and linearity ± 0.2%, range of programmed energy: 0.1 to 99.99 J/cm2, intensity:
UVA (365 nm) 5 mW/cm2, UVB (312 nm) 3 mW/cm2, UVA + UVB: 5.6 + 3.2 mW/cm2, respec-
tively. The selected UV irradiation intensities were 40% and 80% of the Biological Effective Dose
(BED) of 7.5 J/cm2 UV daylight as described by Del Bino et al. [41]. UV 40% BED = 3.0 J/cm2
(= 0.1 J/cm2 UVB + 2.9 J/cm2 UVA); UV 80% = 6.0 J/cm2 (= 0.2 J/cm2 UVB + 5.8 J/cm2 UVA).
Skin viability was assessed in two skin biopsies after 6 days of treatment using methylthiazo-
lyldiphenyl-tetrazolium bromide (MTT, Sigma Aldrich) staining. Total dermal collagen in skin
sections was semi-quantitatively evaluated by Picrosirius Red histochemical staining (using Pic-
ric Acid, Fast Green FCF and Direct Red from Sigma Aldrich) that dyes collagen fibers in pur-
ple-red. The papillary dermis was selected for the analysis, being the portion of the dermis that
shows highest collagen variation in response to treatment. The evaluation was performed by
estimating both color intensity and distribution using IMAGE J (NIH) analysis software, allow-
ing to obtain a semi-quantitative evaluation of dermal collagen (collagen score). Two slides of
each skin sample were processed by image acquisition and related analysis (i.e. 12 images for
each treatment).
For statistical analysis, one-way ANOVA with permutation test was performed, followed by
Tukey’s permutation test.
Molecular modeling
Protein (PDB code: 2IRW) was retrieved from RSCB database [42] and prepared using the
protein preparation wizard from Maestro version 10.4, Schro¨dinger, LLC, New York, NY,
2015. In short, bond orders were set, hydrogens were added, disulfide bridges were created, all
waters were removed and hydrogen bonds were optimized using the automated procedure.
Compounds were docked using Glide (version 6.9, Schro¨dinger, LLC, New York, NY, 2015);
two hydrogen bond constrains for Tyr183 and Ser170 were used. The PyMOL Molecular Graph-
ics System, Version 1.8.0.4 Schro¨dinger, LLC was used to prepare S2 Fig.
Results and discussion
Synthesis of the inhibitors
The biaryl amide scaffold was chosen upon exploring the chemical space of the 11β-HSD1 sub-
strate binding pocket by molecular modeling. All compounds of the designed library consist of
a constant benzoyl moiety bound to a cyclic secondary amine via an amide bond and substi-
tuted in position 3 with an aromatic moiety (benzene or pyridine derivative) (Fig 1). All deriv-
atives were prepared by the same two reaction steps, namely Suzuki-Miyaura cross-coupling
between the constant benzoyl moiety and one of the variable aromatic moieties, and amide
formation between the constant benzoyl moiety and a cyclic secondary amine. In principle,
there is no obvious advantage in performing either step first; moreover, in the Suzuki-Miyaura
11β-HSD1 inhibitors for skin applications
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cross-coupling step, it is indifferent which aromatic partner is employed as an aryl bromide
and which as an aryl boronic acid: as a result, four alternative synthesis strategies are possible
for each library compound (Fig 2).
In the view of future developments, the practicability of the four strategies was compared.
Each of the four routes was applied to prepare at least one of the designed compounds (Fig 2).
All four synthesis routes gave satisfactory results in terms of yields, but strategy B (based on amide
formation between 3-boronobenzoic acid and secondary amine a-f followed by Suzuki-Miyaura
cross-coupling with aryl bromide x1-12) was less practical than the remaining approaches, due to
the need for chromatographic purification after amide formation, whereas the alternative routes
generally allow to obtain the product in pure form after simple extractive work-up. Also, different
literature protocols were tested for the Suzuki-Miyaura cross-coupling step [37, 43, 44], whereas a
standard solution-phase peptide chemistry method employing 1-hydroxybenzotriazole (HOBt)
and water-soluble carbodiimide (EDC×HCl) was employed for all amide formation steps. Regard-
ing the reaction protocols for Suzuki-Miyaura cross-coupling, that of Korolev et al. [37] yielded
particularly good results in terms of low loading of air-stable catalyst and very low amounts by-
products formed. A schematic overview of the synthesized compounds 1b to 12e is given in S1 Fig.
Analysis of biaryl amide derivatives inhibiting 11β-HSD1 measured in
cell lysates
A total of 22 compounds containing a biaryl amide core and differing in their variable ring
substituents (R1) and the cyclic secondary amine substituent (R2) were screened for inhibition
of 11β-HSD1 and 11β-HSD2 activity measured in cell lysates in the presence of 100 nM or
1 μM of the respective compound, using glycyrrhetinic acid (GA, CTRL 1) as a positive con-
trol. For the most active compounds IC50 was determined using eight different inhibitor con-
centrations (an example is shown in S2 Fig).
In a first step, the activities of six compounds bearing a 4-methyl, 3-fluoride substituent R1
and with different cyclic secondary amine R2 substituents were compared. Compounds 3a-e
were very potent 11β-HSD1 inhibitors showing more than 95% inhibition at a concentration
of 1 μM and at least 40% inhibition at 100 nM (Fig 3). Interestingly, the introduction of an aze-
pane ring slightly increased activity (compare 3a with 3e) while retaining selectivity, which
prompted us to expand the structure activity relationship (SAR) data around the azepane
derivatives at a later step.
In this first series (3a-f) only the introduction of a prolinamide group (3f) abolished the
activity towards 11β-HSD1. Visualization of the docked pose of prolinamide compound 3f
revealed that in order to form the expected hydrogen bonds with residues Ser170 and Tyr183 a
negative steric interaction with Ile121 in the binding site arises, and there are no stabilizing
interactions from the prolinamide group (no apparent H-bonds), which may explain the lack
of activity of these compounds (for illustration see S3 Fig). Also, the prolinamide derivative 6f
with a chlorine in 2-position as R1 substituent was inactive towards 11β-HSD1 at 1 μM, for
similar reasons as for 3f.
In a second step, the influence of R1 variations was analyzed while keeping constant either
the 4-methyl piperidine or the azepane moiety. In most cases the exchange of the substituent
in the variable aryl group did not induce a large difference in activity (no greater than a factor
of two). However, the introduction of a carboxamide group in 9b and 10b either at the 3- or
the 4-position resulted in substantial loss of activity. Also the introduction of a 3-hydroxy (8b)
or a 3,4-dimethyl (11e) substituent resulted in lower activity.
Among all compounds tested, 3c was the only one to show slight inhibition of 11β-HSD2
with 81% residual activity at 1 μM. Among the most potent and selective compounds two
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Fig 3. Activity of synthesized compounds toward 11β-HSD1 and 11β-HSD2. Enzyme activity was
measured in lysates of HEK-293 cells expressing recombinant human 11β-HSD1 or 11β-HSD2 as described
in Materials and Methods. Data represent mean from three independent experiments. nd: not determined.
doi:10.1371/journal.pone.0171079.g003
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4-methylpiperidine derivatives (2b, 7b) and two azepane derivatives (3e, 12e) were chosen for
further investigation.
Selectivity of 11β-HSD1 inhibitors over 17β-HSD1 and 17β-HSD2
Since 17β-HSD1 and 17β-HSD2 have important roles in the modulation of active estrogens and
androgens and they share structural similarity with 11β-HSD1 and 11β-HSD2, respectively
[45], the four selected compounds were tested for inhibitory activity against these enzymes.
None of the four compounds inhibited 17β-HSD1 or 17β-HSD2 at a concentration of 1 μM, in
contrast to the positive controls apigenin (CTRL 2) and compound 22 of Vuorinen et al. [40]
(CTRL 3), respectively (S4 Fig).
The short-chain dehydrogenase/reductase (SDR) family comprises more than 80 members
in the human genome [46]. To further assess the selectivity of the newly identified compounds,
additional SDRs that are expressed in skin should be included in the testing in order to avoid,
among others, the inhibition of 3β-HSD involved in steroidogenesis [7, 47], or retinol dehy-
drogenases involved in retinoid metabolism or in the detoxification of unsaturated aldehydes
formed upon oxidative stress [48].
Inhibition of 11β-HSD1 in intact cells
The four inhibitors 2b, 3e, 7b and 12e were tested for their activity in intact HHH7 cells stably
expressing 11β-HSD1 and H6PDH [38]. Cells were incubated at a final concentration of 200
nM cortisone in the presence of 1 μM GA (CTRL 1) as positive control or 100 nM and 1 μM of
the test compounds (Fig 4A). All compounds almost completely inhibited 11β-HSD1 at both
concentrations tested, demonstrating that effective concentrations were reached at the active
site of the enzyme in the endoplasmic reticulum.
Next, the activity of the four selected compounds as inhibitors of the 11β-HSD1-mediated
cortisol production in primary human keratinocytes was determined. Keratinocytes were incu-
bated for 24 h with 1 μM cortisone and the respective inhibitor. Compound CAS 1009373-58-3
(CTRL 4, at 1 μM) was used as positive control. At a concentration of 1 μM all compounds
almost completely inhibited cortisol formation, and the estimated IC50 values were 100 nM or
lower (Fig 4B). The potency of inhibition was 3e> 12e> 7b> 2b. Thus, all four compounds
efficiently blocked cortisol formation in primary human keratinocytes.
Ex vivo human skin experiments
To prepare for topical applications, experiments with skin biopsies were performed. First, UV
irradiation strength to induce moderate skin damage and potential toxic effects of the selected
inhibitors was assessed. Exposure of the skin samples to UV at 3.0 J/cm2 and 6.0 J/cm2 resulted
in a progressive decrease in viability to 90% and 72% (significant compared with unexposed
control, p<0.001), respectively (S5 Fig). Importantly, the addition of inhibitors did not affect
skin viability, thus allowing studying effects of these inhibitors on collagen content in UV-
exposed skin.
Next, the effect of cortisone, which requires 11β-HSD1-dependent conversion to cortisol,
on skin viability and collagen content was analyzed. Treatment of skin biopsies with cortisone
did not significantly lower skin viability despite a trend decrease by 10–15% at 100 nM (S6A
Fig). In contrast, dermal collagen was significantly decreased upon exposure to 10 nM, 100
nM and 1 μM of cortisone by 20–26% (p<0.01, S6B Fig). The simultaneous treatment with
100 nM cortisone and either 10 μM or 100 μM of inhibitor (3e, 2b, or 12e) prevented the corti-
sone-induced collagen decrease (Fig 5).
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Furthermore, in a preliminary set of experiments, skin biopsies were UV irradiated at 3.0 J/cm2
and 6.0 J/cm2 and treated topically with 4 μL of 10 μM or 100 μM of the respective inhibitor,
Fig 4. Inhibition of 11β-HSD1 activity in intact cells. (A), Inhibition of 11β-HSD1-dependent cortisol
formation in intact HEK-293 cells. HEK-293 cells stably co-expressing human 11β-HSD1 and H6PDH were
incubated for 30 min in the presence of 200 nM radiolabeled cortisone and either 1 μM of the positive control
inhibitor glycyrrhetinic acid (CTRL 1) or 100 nM and 1 μM of the respective test compounds. Formation of
cortisol was determined by separation of steroids by TLC and scintillation counting. Data represent mean ± SD
of three independent experiments, each performed in triplicate. (B), Inhibition of 11β-HSD1-dependent cortisol
formation in intact human keratinocytes. Primary human keratinocytes were grown for two days, followed by
incubation for 24 h with 1 μM of cortisone and various concentrations of inhibitor. Compound CAS 1009373-58-
3 (Merck, CTRL 4) was used as positive control. An additional vehicle control was measured in the absence of
exogenous cortisone (black bar). Formation of cortisol was determined by an enzyme immune assay. Data
represent mean ± SD from three experiments. Shapiro-Wilk test was used to assess the normality of data.
One-way analysis of variance (ANOVA) and Dunnett’s multiple-comparison test were performed to evaluate
differences between inhibitor treatments compared to the solvent control. All values were significantly different
(p<0.01) compared to vehicle control in the presence of cortisone, except treatment of keratinocytes with 10
nM 2b.
doi:10.1371/journal.pone.0171079.g004
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followed by determination of collagen III content using a mouse monoclonal anti-collagen III
antibody (Sigma Aldrich). A comparison of the UV exposed vehicle control with the non-irradi-
ated vehicle control revealed a significant decrease in collagen III by about 20% (p<0.01) in Fig 6B
but only a trend in Fig 6A and 6C–6F. Treatment with compound 3e prevented the decrease in
collagen III levels, with significantly higher collagen III at 100 μM upon exposure to 3.0 J/cm2 UV
irradiation (p<0.01) and 6.0 J/cm2 UV irradiation (p<0.05). In the group of biopsies exposed to
6.0 J/cm2 UV irradiation treatment with 100 μM of compounds 2b or 12e resulted in significantly
higher collagen III levels compared with the UV treated vehicle control. In contrast, treatment
with 10 μM of 2b or 12e did not result in significant changes. These initial experiments shown in
Figs 5 and 6 suggest that inhibition of 11β-HSD1 can prevent the decrease of collagen upon expo-
sure of skin biopsies to cortisone and/or UV irradiation.
Nevertheless, future experiments should include time-dependence of UV exposure and
11β-HSD1 inhibitor treatment as well as investigations into gene expression to assess the
potential of such compounds in the prevention of skin damage and skin aging. An increased
expression of 11β-HSD1 upon exposure of skin to UV irradiation was observed previously
[14]. Thus, inhibition of 11β-HSD1 might be beneficial in situations of chronically elevated
glucocorticoid activation in skin to avoid related adverse effects. Besides, CYP11B1 inhibitors
might represent an alternative approach to avoid excessive local glucocorticoid effects due to
enhanced steroidogenic cortisol production upon exposure to UV irradiation [16, 17]. It will
also be important to assess the expression levels and sensitivity to cortisol of GR and MR in
skin. Exposure to UV irradiation lowered epidermal GR expression [14]. Whether this results
in a shift from GR to MR response by glucocorticoids as observed in microglial cells [49]
remains to be investigated.
Fig 5. Reversal of cortisone-mediated decrease in dermal total collagen content upon treatment with
selected compounds. Human skin biopsies were treated topically with 4 μL of 10 μM or 100 μM of the
selected compounds for 6 days. After the first 24 h of incubation with the inhibitors, the skin samples were
simultaneously treated with inhibitor and 100 nM cortisone for the remaining 5 days. Dermal collagen content
was semi-quantitatively assessed by Picrosirius Red histochemical staining. Data represent mean ± SEM
from 6 human biopsies. Shapiro-Wilk test indicated that the data followed a normal distribution and unpaired t-
test was used to test for significant differences. # p<0.01 compared to vehicle control in the absence of
cortisone; * p<0.05, ** p<0.01, *** p<0.001 compared to cortisone treated vehicle control.
doi:10.1371/journal.pone.0171079.g005
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Conclusion
The present study describes novel biaryl amide compounds prepared by Suzuki-Miyaura
cross-coupling. The derivatives were first screened for inhibition of 11β-HSD1 and 11β-HSD2
Fig 6. Effect of selected compounds on dermal collagen III content in UV exposed human skin
samples. Human skin biopsies were treated topically with 4 μL of 10 μM or 100 μM of compound 3e (A,B), 2b
(C,D), or 12e (E,F) and exposed to 3.0 J/cm2 (A,C,E) or 6.0 J/cm2 UV irradiation (B,D,F) for 6 days. Dermal
collagen III expression was detected using a mouse monoclonal anti-collagen III antibody. Data represent
mean ± SEM. Per treatment 12 skin samples were analyzed. The data set presented a normal distribution
using Shapiro-Wilk test and an unpaired t-test was used to test for significant differences. ## p<0.01 for UV
exposed vehicle control vs non-irradiated vehicle control. * p<0.05, ** p<0.01 for UV exposed inhibitor
treated vs UV exposed vehicle control.
doi:10.1371/journal.pone.0171079.g006
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activity measured in cell lysates at concentrations of 1 μM and 100 nM, followed by determina-
tion of IC50 for the most active compounds. Interestingly, the introduction of an azepane ring
slightly increased the inhibitory activity (compare 3a with 3e) while retaining selectivity,
which prompted us to expand the SAR data around the azepane derivatives in a next step.
Among the most potent and selective compounds two 4-methylpiperidine derivatives (2b, 7b)
and two azepane derivatives (3e, 12e) were chosen for further investigation as they were also
found to be selective against 17β-HSD1 and 17β-HSD2 at a concentration of 1 μM. The four
selected inhibitors 2b, 3e, 7b and 12e were tested for their activity in intact HHH7 cells stably
expressing 11β-HSD1 and H6PDH [38]. All four compounds selectively inhibited 11β-HSD1
in the nanomolar range and efficiently blocked cortisol formation in intact primary human
keratinocytes. Three compounds, 2b, 3e, and 12e, were further shown to prevent the corti-
sone-dependent decrease in collagen content in human skin biopsies. Furthermore, the results
from UV irradiated skin biopsies suggest that these compounds may also reduce the decrease
in collagen III content observed in UV exposed skin.
Clearly, further experiments are needed to assess time- and dose-dependent effects of the
selected inhibitors and to optimize UV exposure as well as test the inhibitors at combined
treatment with cortisone and UV exposure. Furthermore, the impact of topical administration
of 11β-HSD1 inhibitors on dermal thickness, number of dermal fibroblasts and keratinocytes
in human skin has to be evaluated, in analogy to the observations in mice [31, 33]. Since 11β-
HSD1 expression in skin has been shown to increase with age and excessive cortisol levels
result in skin atrophy [13, 32], topical application of 11β-HSD1 inhibitors may represent a
promising approach to prevent skin damage and delay skin aging.
Supporting information
S1 Fig. Overview of the synthesized compounds.
(TIF)
S2 Fig. IC50 for 11β-HSD1 of the selected compounds 2b, 3e, 7b and 12e. The selected test
compounds at different concentrations were analyzed for their ability to inhibit 11β-HSD1-de-
pendent conversion of 200 nM cortisone to cortisol. IC50 was calculated for compound 2b (A),
3e (B), 7b (C) and 12e (D) from results obtained from three independent experiments.
(TIF)
S3 Fig. Binding site surfaced view of the docked pose of prolinamide 3f (orange). For clarity
only residues that have major interactions with the ligand are shown. The negative steric inter-
action with Ile121 is indicated by a red dotted line. The interactions with Ser170 and Tyr183 are
shown by yellow dotted lines.
(TIF)
S4 Fig. Selectivity of the 11β-HSD1 inhibiting test compounds over 17β-HSD1 and 17β-
HSD2. The selected test compounds at a concentration of 1 μM were analyzed for their ability
to inhibit 17β-HSD1-dependent conversion of 200 nM estrone to estradiol (A) and the 17β-
HSD2-dependent conversion of 200 nM estradiol to estrone (B). Apigenin (CTRL 2) and com-
pound 22 of Vuorinen et al. [22] (CTRL 3) served as positive controls. Data represent
mean ± SD from three independent experiments.
(TIF)
S5 Fig. Impact of UV irradiation and selected compounds on cell viability in human skin
biopsies. The experiments with human full skin biopsies were performed by Cutech Biotech-
nology. Skin samples were treated topically with vehicle or the respective compounds (4 μL of
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10 μM or 100 μM compound applied on top of each biopsy specimen) for 6 days either in the
absence of UV treatment or upon exposure to 3.0 J/cm2 or 6.0 J/cm2 UV irradiation. Cell via-
bility was determined after 6 days using MTT. Data represent mean ± SEM from 6 human
biopsies.
(TIF)
S6 Fig. Effect of cortisone on cell viability in human skin biopsies. Human skin biopsies
were treated with 0.01 μM, 0.1 μM or 1 μM cortisone for 6 days, followed by assessment of
skin viability using the MTT assay. Data represent mean ± SEM from 6 samples derived from
2 different skin biopsies.  p<0.01 vs vehicle control.
(TIF)
S1 File. Experimental section. Materials and methods for chemistry.
(DOC)
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